Alnylam Pharmaceuticals (ALNY) Other Working Capital Changes (2009 - 2026)

Alnylam Pharmaceuticals has reported Other Working Capital Changes for 18 years, with the latest figure at -$1.6 million in Q1 2026.

• For the quarter ending Q1 2026, Other Working Capital Changes rose 94.02% year-over-year to -$1.6 million; the trailing twelve-month figure through Mar 2026 stood at $143.4 million (up 161.23% YoY), and the FY2025 full-year result was $117.7 million, up 150.0% from the prior year.
• Other Working Capital Changes for Q1 2026 stood at -$1.6 million, down from $149.2 million in the prior quarter.
• The five-year high for Other Working Capital Changes was $241.6 million in Q3 2024, with the low at -$257.5 million in Q4 2024.
• Historically, Other Working Capital Changes has averaged -$4.2 million across 5 years, with a median of -$1.6 million in 2026.
• Annual changes were most pronounced in 2022 — Other Working Capital Changes surged 18370.51% — and 2024, when it plunged 2412.79%.
• Alnylam Pharmaceuticals' Other Working Capital Changes stood at $70.2 million in 2022, then tumbled by 140.3% to -$28.3 million in 2023, then tumbled by 809.76% to -$257.5 million in 2024, then surged by 157.94% to $149.2 million in 2025, then plunged by 101.09% to -$1.6 million in 2026.
• The last three Other Working Capital Changes figures came in at -$1.6 million (Q1 2026), $149.2 million (Q4 2025), and $6.4 million (Q3 2025), per Business Quant data.